Haleon PLC (GB:HLN) has released an update.
Haleon PLC has released their Q1 trading statement for 2024, highlighting the company’s continued commitment to enhancing everyday health through their wide range of consumer health products. Investors and analysts can join a presentation and Q&A session with CFO Tobias Hestler and Head of Investor Relations Sonya Ghobrial, or access the information on Haleon’s website. Haleon is known for its trusted brands in various health categories, including Advil, Sensodyne, and Centrum.
For further insights into GB:HLN stock, check out TipRanks’ Stock Analysis page.